SARS-CoV-2 Spike Peptid
Reaktivität: SARS Coronavirus-2 (SARS-CoV-2)
Wirt: Synthetic
InhA
2 Abbildungen
(3 Referenzen)Kurzübersicht für SARS-CoV-2 Spike Peptid (ABIN6952484)
Target
SARS-CoV-2 Spike
Spezies
SARS Coronavirus-2 (SARS-CoV-2)
Quelle
Synthetic
Applikation
Inhibition Assay (InhA)
-
-
Sequenz
- ANQFNSAIGK IQDSLSSTAS ALGKLQDVVN QNAQALNTLV KQ
-
Produktmerkmale
- 2019-nCov-HR1P
-
Reinheit
- ≥ 95 %
-
Bestandteile
- Each vial contains 100 μg of NET peptide.
-
-
SARS-CoV-2 Spike peptide
Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
SARS-CoV-2 Spike peptide (Cy5)Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
SARS-CoV-2 Spike peptide (Cy5)Reaktivität: SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Powder
-
Lagerung
- RT,4 °C,-20 °C
-
Informationen zur Lagerung
- Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
-
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." in: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." in: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
-
- SARS-CoV-2 Spike
-
Substanzklasse
- Viral Protein
-
Molekulargewicht
- 4386.89
-
Gen-ID
- 43740568
-
UniProt
- P0DTC2
Target
-
Sie sind hier:
